ABSTRACT
Lipoprotein(a) [Lp(a)] is a circulating lipoprotein, and its level is largely determined by variation in the Lp(a) gene (LPA) locus encoding apo(a). Genetic variation in the LPA gene that increases Lp(a) level also increases coronary artery disease (CAD) risk, suggesting that Lp(a) is a causal factor for CAD risk. Lp(a) is the preferential lipoprotein carrier for oxidized phospholipids (OxPL), a proatherogenic and proinflammatory biomarker. Lp(a) adversely affects endothelial function, inflammation, oxidative stress, fibrinolysis, and plaque stability, leading to accelerated atherothrombosis and premature CAD. The INTER-HEART Study has established the usefulness of Lp(a) in assessing the risk of acute myocardial infarction in ethnically diverse populations with South Asians having the highest risk and population attributable risk. The 2018 Cholesterol Clinical Practice Guideline have recognized elevated Lp(a) as an atherosclerotic cardiovascular disease risk enhancer for initiating or intensifying statin therapy.
ABSTRACT
Ocular neovascularization,abnormal formation of new vessels from pre-existing capillaries,is a special pathologic change of many ocular diseases,including diabetic retinopathy and retinopathy of prematurity,etc..Ocular neovascular diseases comprise the common causes of blindness in millions of people.Recent studies showed that kringle domains from many endogenous proteins inhibit the proliferation and migration of endothelial cells in vitro and neovascular formation in vivo.Hence kringle domain with conservative structure has been considered as a potential inhibitor of neovascularization.The update studies on antiangiogenic kringle domains and its inhibition on ocular neovascularization were summarized.